# Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

> **NCT01548404** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 109 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT01548404
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-06
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548404, "Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01548404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*